CIK 0001609809
- Non-accelerated filer
- Smaller reporting company
Seres Therapeutics, Inc.
Sign in to watch- Ticker
- MCRB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 274326290
- Phone
- +1 617-945-9626
- Business address
- 200 SIDNEY STREET, CAMBRIDGE, MA, 02139
- Former names
- Seres Therapeutics, Inc., Seres Health, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $795
- in 4 filings, $795 under 10b5-1 plans
Net −$795. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 39 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2018-01-26 | COOK DAVID N | Exercise or conversion · RESTRICTED STOCK UNITS | −5,000 | 20,000 | ||
| 2018-01-24 | Pomerantz Roger President and CEO | Exercise or conversion | +40,241 | $0.71 | $29K | 324,537 |
| 2018-01-24 | Pomerantz Roger President and CEO | Exercise or conversion · Stock Option (right to buy) | −40,241 | 911,441 | ||
| 2017-12-19 | Aunins John G. | Exercise or conversion | +5,000 | 197,125 | ||
| 2017-12-19 | Aunins John G. | Sale | −1,623 | $10.14 | $16K | 195,502 |
| 2017-12-19 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion | +5,000 | 61,060 | ||
| 2017-12-19 | Aunins John G. Chief Technology Officer & EVP | Sale | −1,623 | $10.14 | $16K | 59,437 |
| 2017-12-19 | Aunins John G. Chief Technology Officer & EVP | Exercise or conversion · Restricted Stock Units | −5,000 | 15,000 | ||
| 2017-07-18 | Pomerantz Roger President and CEO | Exercise or conversion | +100,604 | $0.71 | $71K | 284,296 |
| 2017-07-18 | Pomerantz Roger President and CEO | Exercise or conversion · Stock Option (right to buy) | −100,604 | 951,682 | ||
| 2017-07-07 | Dere Willard H Director | Grant or award · Stock Option (right to buy) | +30,000 | 30,000 | ||
| 2017-06-20 | Kender Richard N Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-20 | AFEYAN NOUBAR Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-20 | Graves Kurt Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-20 | Kim Lorence H. Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-20 | Ausiello Dennis A Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-20 | Behar Gregory Director | Grant or award · Stock Option (right to buy) | +15,000 | 15,000 | ||
| 2017-06-19 | Aunins John G. Chief Technology Officer & EVP | Grant or award · Restricted Stock Units | +20,000 | 20,000 | ||
| 2017-01-26 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Stock Option (right to buy) | +60,000 | 60,000 | ||
| 2017-01-26 | DesRosier Thomas Chief Legal Officer and EVP | Grant or award · Restricted Stock Units | +50,000 | 50,000 |
Page 30 of 34 · 662 trades